{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:53Z","timestamp":1786115093427,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006419","name":"EuroQol Research Foundation","doi-asserted-by":"publisher","award":["2120-RA"],"award-info":[{"award-number":["2120-RA"]}],"id":[{"id":"10.13039\/501100006419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jval.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:19:06Z","timestamp":1783178346000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are Preference-Weighted Cancer-Specific Measures More Sensitive Than Generic Measures? A Comparison of EQ-5D-5L, SF-6Dv2, FACT-8D, and QLU-C10D in Gastrointestinal Cancers"],"prefix":"10.1016","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.06.009_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40273-017-0544-y","article-title":"International regulations and recommendations for utility data for health technology assessment","volume":"35","author":"Rowen","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2026.06.009_bib2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","article-title":"Psychometric properties of the EQ-5D-5L: a systematic review of the literature","volume":"30","author":"Feng","year":"2021","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.jval.2026.06.009_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","article-title":"Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines","volume":"21","author":"Kennedy-Martin","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2026.06.009_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mlr.0000254515.63841.81","article-title":"Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients","volume":"45","author":"Pickard","year":"2007","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.jval.2026.06.009_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18090","article-title":"Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey","volume":"18","author":"Longworth","year":"2014","journal-title":"Health Technol Assess"},{"issue":"8","key":"10.1016\/j.jval.2026.06.009_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10198-021-01337-6","article-title":"Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms","volume":"22","author":"Shah","year":"2021","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2026.06.009_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcpo.2016.09.005","article-title":"QALYs as a measure of value in cancer","volume":"11","author":"Devlin","year":"2017","journal-title":"J Cancer Policy"},{"issue":"6","key":"10.1016\/j.jval.2026.06.009_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jval.2021.01.007","article-title":"The functional assessment of cancer therapy eight dimension (FACT-8D), a multi-attribute utility instrument derived from the cancer-specific FACT-General (FACT-G) Quality of Life Questionnaire: development and Australian value set","volume":"24","author":"King","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.06.009_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s41669-023-00448-5","article-title":"United States value set for the functional assessment of cancer therapy-general eight dimensions (FACT-8D), a cancer-specific preference-based quality of life instrument","volume":"8","author":"King","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jval.2026.06.009_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115235","article-title":"Cancer-specific utility instrument for health economic evaluations: a synopsis of the EORTC QLU-C10D user manual and current validity evidence","volume":"217","author":"Seyringer","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2026.06.009_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111592","article-title":"The EORTC QLU-C10D distinguished better between cancer patients and the general population than PROPr and EQ-5D-5L in a cross-sectional study","volume":"177","author":"D\u00f6hmen","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.009_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-020-01611-w","article-title":"Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer","volume":"18","author":"Hagiwara","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2026.06.009_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-025-02410-x","article-title":"Utility score mapping from FACT-G to EQ-5D-5L and SF-6Dv2 in breast and colorectal cancer patients: a focus on beta mixture models","volume":"23","author":"Poder","year":"2025","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"10.1016\/j.jval.2026.06.009_bib14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40273-025-01501-3","article-title":"Validation of the cancer-specific preference-based measure EORTC QLU-C10D against the generic instruments EQ-5D-5L and SF-6Dv2 in a prospectively collected sample of patients with cancer in Austria and France","volume":"43","author":"Pilz","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2026.06.009_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111965","article-title":"EORTC QLU-C10D was similarly valid and sensitive as EQ-5D-5L but more responsive to cancer patients\u2019 health deterioration","volume":"187","author":"Wang","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jval.2026.06.009_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10198-024-01730-x","article-title":"Comparing the measurement properties of the EQ-5D-5L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin\u2019s lymphoma","volume":"26","author":"Xu","year":"2025","journal-title":"Eur J Health Econ"},{"issue":"6","key":"10.1016\/j.jval.2026.06.009_bib17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10198-022-01523-0","article-title":"Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients","volume":"24","author":"Pan","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2026.06.009_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10198-025-01815-1","article-title":"Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients","volume":"27","author":"Zhang","year":"2025","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2026.06.009_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-024-02097-4","article-title":"Digestive cancers: mechanisms, therapeutics and management","volume":"10","author":"Zhan","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"10.1016\/j.jval.2026.06.009_bib20","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/CM9.0000000000003225","article-title":"Burden of six major types of digestive system cancers globally and in China","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"10.1016\/j.jval.2026.06.009_bib21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.6004\/jnccn.2009.0056","article-title":"NCCN clinical practice guidelines in oncology: colon cancer","volume":"7","author":"Engstrom","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.jval.2026.06.009_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Eval Health Prof"},{"issue":"14","key":"10.1016\/j.jval.2026.06.009_bib23","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0959-8049(00)00186-6","article-title":"A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients","volume":"36","author":"Bjordal","year":"2000","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.jval.2026.06.009_bib24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items","volume":"18","author":"Hays","year":"2009","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jval.2026.06.009_bib25","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s11136-020-02419-3","article-title":"The Simplified Chinese version of SF-6Dv2: translation, cross-cultural adaptation and preliminary psychometric testing","volume":"29","author":"Wu","year":"2020","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jval.2026.06.009_bib26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.06.009_bib27","unstructured":"Cao Y, King MT, Norman R, et al. Developing a Chinese Value Set for the FACT-8D, a Cancer-Specific Multi-attribute Utility Instrument Based on the FACT-General Questionnaire. Under peer review."},{"issue":"12","key":"10.1016\/j.jval.2026.06.009_bib28","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s11136-024-03776-z","article-title":"Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D","volume":"33","author":"Cao","year":"2024","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2026.06.009_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40258-024-00919-8","article-title":"The Short Form 6 dimensions (SF-6D): development and evolution","volume":"23","author":"Mukuria","year":"2025","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"10.1016\/j.jval.2026.06.009_bib30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40273-020-00997-1","article-title":"Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension","volume":"39","author":"Wu","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2026.06.009_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"Quantitative methods in psychology: a power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"10.1016\/j.jval.2026.06.009_bib32","first-page":"1977","article-title":"Using Cliff\u2019s delta as a non-parametric effect size measure: an accessible web app and R tutorial","volume":"29","author":"Meissel","year":"2024","journal-title":"Pract Assess Res Eva"},{"key":"10.1016\/j.jval.2026.06.009_bib33","series-title":"Dictionary of Pharmaceutical Medicine","author":"Nahler","year":"2009"},{"key":"10.1016\/j.jval.2026.06.009_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1477-7525-8-4","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"8","author":"Pickard","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2026.06.009_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111487","article-title":"Systematic review reveals that EQ-5D minimally important differences vary with treatment type and may decrease with increasing baseline score","volume":"174","author":"Cheng","year":"2024","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jval.2026.06.009_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jval.2024.11.006","article-title":"A systematic literature review of important and meaningful differences in the EQ-5D index and visual analog scale scores","volume":"28","author":"Al Sayah","year":"2025","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2026.06.009_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219854","article-title":"Intraclass correlation\u2014A discussion and demonstration of basic features","volume":"14","author":"Liljequist","year":"2019","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.jval.2026.06.009_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Understanding Bland Altman analysis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.jval.2026.06.009_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1657249","article-title":"Assessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China","volume":"15","author":"Sun","year":"2025","journal-title":"Front Oncol"},{"issue":"10242","key":"10.1016\/j.jval.2026.06.009_bib40","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2026.06.009_bib41","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.jval.2026.06.009_bib42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/erp.11.57","article-title":"Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials","volume":"11","author":"Hamidou","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"10.1016\/j.jval.2026.06.009_bib43","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s11136-024-03761-6","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0","volume":"33","author":"Mokkink","year":"2024","journal-title":"Qual Life Res"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:41:23Z","timestamp":1785976883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S1098301526025283"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are Preference-Weighted Cancer-Specific Measures More Sensitive Than Generic Measures? A Comparison of EQ-5D-5L, SF-6Dv2, FACT-8D, and QLU-C10D in Gastrointestinal Cancers","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}